NCT00002635已完成2 期
PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 6
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma.
详细描述
OBJECTIVES: I. Assess the antitumor activity of aminocamptothecin (9-AC) administered by 72-hour infusion in patients with advanced cutaneous T-cell lymphoma. II. Assess the toxic effects of 9-AC administered on this schedule.
OUTLINE: Single-Agent Chemotherapy. Aminocamptothecin, 9-AC, NSC-603071.
PROJECTED ACCRUAL: A total of 30 patients will be accrued; if no more than 1 response is seen in the first 15 patients, the study will close. Probable duration of study is 18 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerLung CancerNCT00003154Case Comprehensive Cancer Center19
已完成
2 期
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the EsophagusGastric CancerEsophageal CancerNCT00003192University of Chicago15
已完成
2 期
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian CancerOvarian CancerNCT00002671NYU Langone Health
已完成
2 期
Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney CancerKidney CancerNCT00003551Emory University
已完成
2 期
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the PeritoneumPrimary Peritoneal Cavity CancerOvarian CancerNCT00003523Gynecologic Oncology Group